CalciMedica Inc CALC

Healthcare

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).

NDAQ:CALC - Post by User

CalciMedica Inc

<< Previous

Bullboard Posts

Next >>

Post by yukon_goldon Nov 17, 2022 9:11pm

256 Views

Post# 35109113

Graycliff Exploration Fall Mining Showcase: Watch the Replay

Graycliff Exploration at the RedCloud Fall Mining Showcase 2022: Watch the Replays

Thank you to everybody who attended Graycliff's presentation at the RedCloud Fall Mining Showcase last week. In case you missed it, watch our presentation replay where James Macintosh, President, CEO and Director, provided a full company overview, exploration updates, and a rundown of upcoming milestones.

Click on the video below to watch.

James Macintosh also joined RedCloud's Mark Bunting for a chat about the Company and why it should be on the investors' radars. Click on the image below to hear exclusive project updates.